|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Diabetes > Rezulin
(troglitazone)
Rezulin (troglitazone) Parke-Davis (removed from US market)
Related Topics:
News & Research:
-
Insulin-sensitizing Drug Cut Diabetes Risk - Science Daily, 4/12/05 -
"troglitazone lowered diabetes onset
by 75 percent"
-
Troglitazone Improves Endothelial Function And Fasting Plasma Insulin Concentrations - Doctor's Guide, 3/4/03
- Troglitazone Improves Cardiovascular Risk Factors Better Than Metformin In Type 2 Diabetes - Doctor's Guide, 3/11/02
- Troglitazone Augments Fatty Acid Flux Suppression By Insulin - Doctor's Guide, 2/25/02
- Troglitazone Drug Helps non-Diabetic Patients Lose Weight - Doctor's Guide, 6/20/01
- Troglitazone Improves Ovulation And Hirsutism In Women With Polycystic Ovary Syndrome - Doctor's Guide, 4/11/01
- Troglitazone Safe And Effective In Triple Therapy - Doctor's Guide, 6/21/99
- Troglitazone Successful As Combination Therapy For Diabetics - Doctor's Guide, 6/21/99
- FDA, Parke-Davis Urge Limits On Rezulin Use - Doctor's Guide, 6/17/99
- Diabetes Drug Troglitazone Slows Tumour Cells Growth - Doctor's Guide, 3/30/99
- FDA Panel Says Rezulin Should Stay On Market - Doctor's Guide, 3/29/99
- Metformin/Troglitazone Combination Improves Diabetes Control - Doctor's Guide, 3/25/98
- Rezulin Labeling Changes Result Of Potential Liver Injury Risk - Doctor's Guide, 11/6/97
- Rezulin For Type II Diabetes Cleared By FDA - Doctor's Guide, 1/30/97
- NIH Tests Rezulin as Part of Prevention Study - Doctor's Guide, 1/30/97
Abstracts:
-
Thiazolidinedione (TZD) Use and Bone Loss in Older Diabetic
Adults - J Clin Endocrinol Metab. 2006 Apr 11 - "each year of TZD use was associated
with greater bone loss at the whole body (additional loss of -0.61% per year;
95% CI: -1.02, -0.21% per year), lumbar spine (-1.23% per year; 95% CI: -2.06,
-0.40% per year), and trochanter (-0.65% per year; 95% CI: -1.18, -0.12% per
year) in women, but not men, with diabetes"
Related Sites:
70526
|
